BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells
BioAdaptives (OTC: BDPT) announced upcoming commercial availability of XcellaraHeart™, a cardiovascular wellness supplement combining the Xcellara™ stem/progenitor cell mobilization base with Tanshinone IIA, a Danshen-derived compound.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioAdaptives (OTC: BDPT) announced upcoming commercial availability of XcellaraHeart™, a cardiovascular wellness supplement combining the Xcellara™ stem/progenitor cell mobilization base with Tanshinone IIA, a Danshen-derived compound. The Xcellara™ base is supported by a randomized, double-blind, placebo-controlled human clinical trial showing an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks.
According to BioAdaptives, XcellaraHeart™ targets two areas: stem/progenitor cell “supply” and cardiovascular repair-related signaling support via pathways studied around the SDF-1α/CXCR4 chemokine axis. A scientific evidence dossier and ordering will be available online, with orders opening August 1, 2026 and first deliveries expected in early August.
Details
News Market Reaction – BDPT
On Jul 15, the day this news came out, BDPT closed 233.33% above the previous close.
Data tracked by StockTitan Argus for the Jul 15 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology
LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara™ line of stem cell mobilization supplements, today announced the upcoming commercial availability of XcellaraHeart™, a premium cardiovascular wellness formula that integrates two complementary areas of cellular health science: stem/progenitor cell mobilization and cardiovascular repair signaling support.
XcellaraHeart™ is built on the Company’s Xcellara™ base, which is supported by a randomized, double-blind, placebo-controlled human clinical trial documenting an average
The second component of the formula is Tanshinone IIA, a natural bioactive compound derived from Danshen root (Salvia miltiorrhiza). Tanshinone IIA has been studied in peer-reviewed cardiovascular research for its effects on the SDF-1α/CXCR4 chemokine axis, a signaling pathway linked to cellular trafficking, cardiovascular repair biology, and tissue-specific signaling.
XcellaraHeart™ was developed around a two-part cardiovascular-wellness strategy:
- Supply: The Xcellara™ base is supported by a randomized, double-blind, placebo-controlled human clinical trial showing an average
268.8% increase in circulating primitive stem/progenitor-type cells after four weeks. - Signaling: Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair-response biology.
“Traditional cardiovascular supplements often focus on circulation, antioxidant status, or vascular elasticity,” said James Keener, CEO of BioAdaptives® Inc. “XcellaraHeart™ was developed to take a broader approach, combining the Xcellara™ stem/progenitor-cell mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its role in the SDF-1α/CXCR4 signaling pathways linked to cellular trafficking and cardiovascular wellness.”
BioAdaptives® developed XcellaraHeart™ based on the hypothesis that increasing circulating stem/progenitor-type cells may be more meaningful when paired with nutrients that support tissue-specific signaling pathways. The Company believes Tanshinone IIA is a particularly compelling candidate for cardiovascular wellness because of its long research history and published evidence on cardiovascular signaling pathways.
The complete scientific evidence dossier for the formulation is available at products.xcellara.com/science. The dossier will separate findings from BioAdaptives’ human clinical research on the Xcellara™ base, published research on Tanshinone IIA, and the Company’s product-development rationale for combining the two.
XcellaraHeart™ will be available for order at products.xcellara.com/xcellaraheart, starting Aug. 1, 2026, with first deliveries expected in early August. General information on new products awaiting rollout is available at products.xcellara.com.
About BioAdaptives® Inc.
BioAdaptives® Inc. is the developer of the Xcellara™ line of stem cell mobilization and tissue-homing supplements. The Company’s flagship Xcellara™ base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a
The complete scientific evidence dossier for the XcellaraHeart™ formulation will be available at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara™ base from published research on Tanshinone IIA and from the Company’s product-development rationale for combining the two.
Availability
XcellaraHeart™ will be available for order at products.xcellara.com/xcellaraheart starting August 1, 2026, with first deliveries expected soon after. General information on new products awaiting rollout is available at products.xcellara.com.
Regulatory Disclaimer
These statements have not been evaluated by the Food and Drug Administration. XcellaraHeart™ is not intended to diagnose, treat, cure, or prevent any disease. Xcellara™ is a trademark of BioAdaptives® Inc.
About BioAdaptives, Inc.
BioAdaptives, Inc. develops and markets science-based health and wellness products for humans and animals. Its formulations are grounded in published research on nutrition, adaptogens, and cellular health, with a focus on supporting normal physiological function.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding product positioning, intended benefits, market opportunity, and future business strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. BioAdaptives undertakes no obligation to update these statements except as required by law.
INVESTOR & MEDIA CONTACT
Emily Harrison
Investor Relations, BioAdaptives, Inc.
702-703-1233 | info@bioadaptives.com | www.bioadaptives.com
X – @BioAdaptivesInc
James Keener, CEO
BioAdaptives® Inc.
Las Vegas, NV
702-334-4424
Ewells@bioadaptives.com
products.xcellara.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.